

Daily Research Report

Dt.: 08 Oct, 2026

INDEX	NIFTY	BANKNIFTY	USDINR
Outlook	Neutral	Neutral	Neutral

INSTITUTIONAL TRADING ACTIVITY IN CRS.

Category	Buy Value	Sell Value	Net Value
FII	12577.96	18699.33	-6121.37
DII	18707.03	14110.66	+4596.57

TRADE STATISTICS FOR 07/10/2026

Instrument	No. of Contracts	Turnover (Cr.)	Put Call Ratio
Index Fut.	90706	14011.72	
Stock Fut.	910762	61095.71	
Index Opt.	66687798	9906117	0.97
Stock Opt.	5635216	391955.8	
F&O Total	73324482	10373180	

Nifty Action: 07/10/2026



PIVOT TABLE					
	R2	R1	PIVOT	S1	S2
NIFTY	22799	22695	22624	22527	22456
BANKNIFTY	55713	55384	55014	54652	54316

NIFTY FUT.			
	TRIGGER	T1	T2
Above	22850	23010	23195
Below	22200	22022	21897

BANK NIFTY FUT.			
	TRIGGER	T1	T2
Above	55500	56450	57072
Below	54000	53524	52178

NIFTY CHART



Nifty reversed sharply from the 22,800 resistance zone yesterday, declining back towards 22,600 support after the RBI MPC raised the repo rate by 25 bps to 5.50% and shifted its stance to calibrated tightening. The move has weakened the immediate rebound structure, with 22,800 now emerging as a crucial hurdle. The index needs to reclaim this level to revive the recovery towards 23,000. On the downside, 22,600 remains the immediate make-or-break support, followed by 22,400 and 22,000. Derivatives data also remains cautious. Nearest-expiry PCR slipped to 0.81 from 1.13, while fresh Call OI additions were concentrated at 22,800, 22,600 and 23,000, indicating rising overhead supply. Put OI witnessed notable unwinding at 22,700 and 22,450, while the broader PCR stood at 0.89, reflecting a defensive setup. Yesterday's rejection near 22,800 and the bearish reversal candle warrant caution, although the oversold setup and positive price-RSI divergence could limit aggressive downside. With TCS Q2 results due today and crude remaining elevated, volatility is likely to stay high. Traders should avoid aggressive longs below 22,800 and monitor 22,600 closely; a sustained break below this level would weaken the rebound further.

Trade Scanner: ALKEM, ANGELONE, BHARTIARTL, CANBK, GVT&D, KEI, MAHABANK, PNBHOUSING, SUPREMEIND, UNIONBANK, VBL. ABCAPITAL, AUBANK, AUROPHARMA, BDL, BIOCON, DIXON, EICHERMOT, GODREJCP, IDFCFIRSTB, INDIGO, MARUTI, NYKAA, UNOMINDA, WIPRO.

RESEARCH DESK: Sacchitanand Uttkar - VP - Research (Derivatives & Technicals)

Disclaimer: Investments in securities market are subject to market risk, read all the related documents carefully before investing.

The securities quoted are for illustration only and are not recommendatory | Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Disclaimer: This document is for private circulation and information purpose only and should not be regarded as an investment, trading, taxation, legal or price risk management advice. In no circumstances it is considered as an offer to sell or a solicitation of any offer to buy or sell the Equity derivatives mentioned herein. We and our affiliates, group companies, directors and employees, and directors and employees of our affiliates and group companies, including persons involved in the preparation or issuance of this material may (a) have positions in Equity (derivatives or physical) mentioned hereby or (b) have other positions which might have conflicting interest with respect to any related information. The information contained hereby may have been taken from sources which we believe are reliable. We do not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinion expressed reflects judgments at this date and are subject to change without notice. Risk of loss in Equity derivatives trading can be substantial. Persons trading in Equity Derivatives should consider the suitability of trading based upon their resources, risk appetite and other relevant information; and understand that statements regarding future prospects may not be realized.